Literature DB >> 27013409

Scientific Advances in Lung Cancer 2015.

Anne S Tsao1, Giorgio V Scagliotti2, Paul A Bunn3, David P Carbone4, Graham W Warren5, Chunxue Bai6, Harry J de Koning7, A Uraujh Yousaf-Khan7, Annette McWilliams8, Ming Sound Tsao9, Prasad S Adusumilli10, Ramón Rami-Porta11, Hisao Asamura12, Paul E Van Schil13, Gail E Darling14, Suresh S Ramalingam15, Daniel R Gomez16, Kenneth E Rosenzweig17, Stefan Zimmermann18, Solange Peters19, Sai-Hong Ignatius Ou20, Thanyanan Reungwetwattana21, Pasi A Jänne22, Tony S Mok23, Heather A Wakelee24, Robert Pirker25, Julien Mazières26, Julie R Brahmer27, Yang Zhou28, Roy S Herbst29, Vassiliki A Papadimitrakopoulou1, Mary W Redman30, Murry W Wynes31, David R Gandara32, Ronan J Kelly33, Fred R Hirsch34, Harvey I Pass35.   

Abstract

Lung cancer continues to be a major global health problem; the disease is diagnosed in more than 1.6 million new patients each year. However, significant progress is underway in both the prevention and treatment of lung cancer. Lung cancer therapy has now emerged as a "role model" for precision cancer medicine, with several important therapeutic breakthroughs occurring during 2015. These advances have occurred primarily in the immunotherapy field and in treatments directed against tumors harboring specific oncogenic drivers. Our knowledge about molecular mechanisms for oncogene-driven tumors and about resistance to targeted therapies has increased quickly over the past year. As a result, several regulatory approvals of new agents that significantly improve survival and quality of life for patients with lung cancer who have advanced disease have occurred. The International Association for the Study of Lung Cancer has gathered experts in different areas of lung cancer research and management to summarize the most significant scientific advancements related to prevention and therapy of lung cancer during the past year.
Copyright © 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adjuvant chemotherapy; Biomarkers; Cancer prevention; Gene mutations; Immunotherapy; Lung cancer; Master protocols; Pathology; Radiotherapy; Screening; Smoking cessation; Staging; Surgery; Targeted therapy; Value of therapy

Mesh:

Year:  2016        PMID: 27013409     DOI: 10.1016/j.jtho.2016.03.012

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  95 in total

1.  Cetuximab combined with natural killer cells therapy: an alternative to chemoradiotherapy for patients with advanced non-small cell lung cancer (NSCLC).

Authors:  Shuzhen Liang; Mao Lin; Lizhi Niu; Kecheng Xu; Xiaohua Wang; Yingqing Liang; Mingjie Zhang; Duanming Du; Jibing Chen
Journal:  Am J Cancer Res       Date:  2018-05-01       Impact factor: 6.166

Review 2.  The emerging treatment landscape of targeted therapy in non-small-cell lung cancer.

Authors:  Min Yuan; Li-Li Huang; Jian-Hua Chen; Jie Wu; Qing Xu
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

Review 3.  Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)-from morphology to molecular testing.

Authors:  Luisella Righi; Francesca Franzi; Francesca Montarolo; Gaia Gatti; Massimo Bongiovanni; Fausto Sessa; Stefano La Rosa
Journal:  J Thorac Dis       Date:  2017-05       Impact factor: 2.895

4.  Neoadjuvant PD-1 blockade in non-small cell lung cancer: what else do we need to do?

Authors:  Wei Guo; Su Yang; Wentian Zhang; Hecheng Li; Bo Lu
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

Review 5.  Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC.

Authors:  Alex Friedlaender; Giuseppe Banna; Sandip Patel; Alfredo Addeo
Journal:  Curr Treat Options Oncol       Date:  2019-09-04

6.  CD38 knockout suppresses tumorigenesis in mice and clonogenic growth of human lung cancer cells.

Authors:  Xiangning Bu; Jiro Kato; Julie A Hong; Maria J Merino; David S Schrump; Frances E Lund; Joel Moss
Journal:  Carcinogenesis       Date:  2018-02-09       Impact factor: 4.944

7.  Molecular alterations in a new cell line (KU-Lu-MPPt3) established from a human lung adenocarcinoma with a micropapillary pattern.

Authors:  Yukiko Matsuo; Kazu Shiomi; Dai Sonoda; Masashi Mikubo; Masahito Naito; Yoshio Matsui; Tsutomu Yoshida; Yukitoshi Satoh
Journal:  J Cancer Res Clin Oncol       Date:  2017-11-01       Impact factor: 4.553

8.  The impact of exogenous CO releasing molecule CORM-2 on inflammation and signaling of orthotopic lung cancer.

Authors:  Li Shao; Congyang Liu; Shuhua Wang; Jiannan Liu; Li Wang; Liping Lv; Yong Zou
Journal:  Oncol Lett       Date:  2018-06-26       Impact factor: 2.967

9.  USP10 inhibits lung cancer cell growth and invasion by upregulating PTEN.

Authors:  Jia Sun; Tianxiang Li; Yinying Zhao; Lirong Huang; Hua Sun; Hui Wu; Xiufeng Jiang
Journal:  Mol Cell Biochem       Date:  2017-08-29       Impact factor: 3.396

Review 10.  The Current Landscape of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer: Emerging Treatment Paradigms and Future Directions.

Authors:  Angel Qin; Shirish Gadgeel
Journal:  Target Oncol       Date:  2017-12       Impact factor: 4.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.